Clinical Trial Update: Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 pharmacokinetic evaluation of G3139 (oblimersen sodium) in advanced melanoma patients, including those with normal hepatic function and moderate hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• G3139 (oblimersen sodium) (oblimersen sodium)

Snippet

Sponsor: Genta Incorporated | Conditions: Advanced Melanoma and Normal or Impaired, Hepatic Function | Phase 2, Phase 3 | Status: TERMINATED